Unsere Publikationen

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Link
https://doi.org/10.1002/acn3.51206
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J.
Verlag
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212.
Zum Eintrag

On the reliability of examining dual-tasking abilities using a novel e-health device—a proof of concept study in multiple sclerosis

Link
https://doi.org/10.3390/jcm9113423
Tags
Management & ScienceeHealth
Jahr
2020
Autoren
Böttrich N, Mückschel M, Dillenseger A, Lange C, Kern R, Ziemssen T, Beste C.
Verlag
J Clin Med. 2020 Oct 25;9(11):3423.
Zum Eintrag

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Link
https://doi.org/10.1177/1352458519888610
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.
Verlag
Mult Scler. 2020 Dec;26(14):1866-1876.
Zum Eintrag

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

Link
https://doi.org/10.1038/s41598-020-62756-8
Tags
Neuroimmunologie
Jahr
2020
Autoren
Jin M, Günther R, Akgün K, Hermann A, Ziemssen T.
Verlag
Sci Rep 2020;10(1).
Zum Eintrag

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Link
https://doi.org/10.1007/s40120-020-00191-7
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Bertolotto A, Arroyo R, Celius EG, Comi G, Havrdova EK, Honeycutt WD, Hunter SF, Izquierdo G, Kornek B, Miller T, Mitsikostas DD, Singer BA, Ziemssen T, Chung L, Daizadeh N, Afsar S, Hashemi L, Senior P.
Verlag
Neurol Ther. 2020 Dec;9(2):443-457.
Zum Eintrag

Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study

Link
https://doi.org/10.1111/ene.14432
Tags
Multiple SkleroseManagement & Science
Jahr
2020
Autoren
Schriefer D, Haase R, Ettle B, Ziemssen T.
Verlag
Eur J Neurol 2020;27(12):2531-2538.
Zum Eintrag

Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Link
https://doi.org/10.1002/acn3.51206
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J.
Verlag
Ann Clin Transl Neurol. 2020 Nov;7(11):2199-2212.
Zum Eintrag

Ofatumumab versus Teriflunomide

Link
https://doi.org/10.1056/nejmoa1917246
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Ziemssen T, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups.
Verlag
N Engl J Med. 2020 Aug 6;383(6):546-557.
Zum Eintrag
31 32 33 34 35

Publikationen durchsuchen

Publikationen filtern

Filters
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Show AllHide
Jahr
-